The ability to foster a competitive and sustainable future supplier base is integral to the health of Gavi-supported vaccine markets. By complementing the vertical vaccine markets view developed during Gavi 4.0 with cross-cutting geographical and supplier portfolio views, Gavi 5.0 supports a more sophisticated engagement with an increasingly diverse vaccine supplier base, and more flexibility to adapt in the wake of post-COVID disruptions.  

The Alliance will rely on a novel approach based on three distinct lenses to build a comprehensive view of the vaccine supplier base.

1. Macro lens: Overarching trends and difficulties across various suppliers which impact the health of a supply base
2. Individual Supplier Lens: Challenges observed in individual supplier health
3. Vaccine Market Lens: Supply-related risk exposure of vaccine markets and assessment of supplier-specific priorities. See Market shaping roadmaps for more detail.  

Market Outcomes: The Alliance will ensure a future where its vaccine supplier base is diverse and competitive by achieving several important market outcomes: adequate capabilities and sustainability of suppliers, functionality of national regulatory agency (NRA), competitive dynamics that improve supply security and affordability without leading to supply security risks, plans to develop new regional/national manufacturing capabilities that improve vaccine access, long-term supply security in the face of new disease outbreaks, and partnerships between manufacturers to develop novel vaccines and new technology platforms. 

Cultivating healthy demand is just as important as considering vaccine supply. Healthy demand is defined, from a market perspective, as that which is timely, predictable, sustainable, balanced, and driven by evidence-based decisions and timely policies.

Market Outcomes: Important market outcomes for this strategic priority include up to date global guidelines, shorter timelines for in-country regulatory approval processes for vaccines, strengthened approaches to evidence-based decision making, a deeper understanding of country product preferences, and actions avoiding serious market failures due to unbalanced demand.

Establishing an enabling environment for transformational innovation is crucial to overcoming key challenges in the development of new immunisation-related products. The innovations can be classified as belonging to one of the following:

1. Vaccine Product innovation: New improved products or adaptations of existing products for Gavi-supported antigens that provide measurable programmatic or financial benefits to LMICs.
2. Antigen innovation: Novel vaccines addressing disease for which there is no vaccine solution yet
3. Other immunisation-product innovation: Any non-antigen related products (e.g., CCE and diagnostics) 

New approaches, tools and mechanisms will be designed through a learning-based approach and tested for one innovation, refined, and then deployed to other innovations. The innovations identified in the Market Shaping Roadmaps will be prioritised based on country needs and contribution to Gavi’s goals on coverage and equity and added to VIPS priorities. 

Market Outcomes: Three main outcomes accompany this strategic priority. These include: enhanced clarity on country-specific immunisation product needs based on public health need, sustained resources to accelerate the process of vaccine innovation (including development and access), and de-risked investments to incentivise this development.